Literature DB >> 18059506

Bevacizumab: the need for controlled studies to move forward.

Yvonne M Buys.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18059506     DOI: 10.3129/i07-176

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


× No keyword cloud information.
  2 in total

Review 1.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

2.  Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

Authors:  Dimitrios A Karagiannis; Ioannis D Ladas; Efstratios Parikakis; Ilias Georgalas; Athanasios Kotsolis; Giorgos Amariotakis; Vasileios Soumplis; Panagiotis Mitropoulos
Journal:  Clin Interv Aging       Date:  2009-12-29       Impact factor: 4.458

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.